<DOC DOCNO="bn/voa/01/voa_0181@0181@voa@bn@en@on">
<TEXT PARTNO="000">
<COREF ID="0" TYPE="IDENT">An international team</COREF> is developing <COREF ID="11" TYPE="IDENT">a vaccine against <COREF ID="2" TYPE="IDENT">Alzheimer 's Disease</COREF></COREF> and <COREF ID="0" TYPE="IDENT">they</COREF> are trying <COREF ID="11" TYPE="IDENT">it</COREF> out on a new and improved mouse model of the onus .
<COREF ID="9" TYPE="IDENT">Correspondent Jessica Berman</COREF> explains .
Scientists working on <COREF ID="11" TYPE="IDENT">a vaccine against <COREF ID="2" TYPE="IDENT">Alzheimer 's</COREF></COREF> give a progress report this week in <COREF ID="16" TYPE="IDENT"><COREF ID="17" TYPE="APPOS" SUBTYPE="ATTRIB">the journal</COREF> <COREF ID="17" TYPE="APPOS" SUBTYPE="HEAD">Nature</COREF></COREF> .
<COREF ID="11" TYPE="IDENT">The vaccine</COREF> has only been tested *-1 in <COREF ID="6" TYPE="IDENT">mice that *T*-2 have been bred *-3 *PRO*-4 to have a form of <COREF ID="2" TYPE="IDENT">Alzheimer 's Disease</COREF> very similar to that of humans</COREF> .
According to <COREF ID="29" TYPE="IDENT">University of Toronto researcher David Westaway</COREF> , <COREF ID="31" TYPE="IDENT">another team of scientists</COREF> last year took the first step toward an <COREF ID="2" TYPE="IDENT">Alzheimer 's</COREF> vaccine .
<COREF ID="31" TYPE="IDENT">That team</COREF> <COREF ID="VOA20001222.2000.0865.mrg-E2" TYPE="IDENT">injected</COREF> <COREF ID="38" TYPE="IDENT">a small amount of amyloid protein , which *T*-1 accumulates in brains of <COREF ID="2" TYPE="IDENT">Alzheimer 's</COREF> patients</COREF> and injected <COREF ID="38" TYPE="IDENT">it</COREF> in <COREF ID="6" TYPE="IDENT">the mice 's</COREF> abdomens .
<COREF ID="VOA20001222.2000.0865.mrg-E2" TYPE="IDENT">The injection</COREF> prompted <COREF ID="6" TYPE="IDENT">the animals '</COREF> immune systems *PRO*-1 to kick in and clean up the amyloid deposits in <COREF ID="6" TYPE="IDENT">the rodents '</COREF> brains .
But <COREF ID="6" TYPE="IDENT">those mice</COREF> never <COREF ID="VOA20001222.2000.0865.mrg-E3" TYPE="IDENT">had</COREF> any difficulties with learning and memory .
In <COREF ID="29" TYPE="IDENT">Dr. Westaway 's</COREF> view , <COREF ID="VOA20001222.2000.0865.mrg-E3" TYPE="IDENT">this</COREF> made <COREF ID="11" TYPE="IDENT">the vaccine</COREF> sort of pointless , since <COREF ID="61" TYPE="IDENT">learning and memory problems</COREF> are a hallmark of <COREF ID="2" TYPE="IDENT">Alzheimer 's Disease</COREF> .
So <COREF ID="0" TYPE="IDENT"><COREF ID="29" TYPE="IDENT">his</COREF> research team</COREF> decided *PRO*-1 to test a vaccine in <COREF ID="VOA20001222.2000.0865.mrg-E7" TYPE="IDENT">mice with <COREF ID="2" TYPE="IDENT">Alzheimer 's</COREF> more like that seen * in many humans</COREF> .
Now normally <COREF ID="2" TYPE="IDENT">Alzheimer 's Disease</COREF> might have <COREF ID="61" TYPE="IDENT">this strong deficit in learning and memory , actually in <COREF ID="0" TYPE="IDENT">our</COREF> experiments the ability *PRO* to navigate around a small tank of water *PRO* using cues pinned * up on the wall of the testing room</COREF> , and once <COREF ID="0" TYPE="IDENT">we</COREF> started *-1 immunizing <COREF ID="VOA20001222.2000.0865.mrg-E7" TYPE="IDENT">the mice</COREF> against the <COREF ID="2" TYPE="IDENT">Alzheimer Disease</COREF> peptides then the performance showed a dramatic improvement such as <COREF ID="VOA20001222.2000.0865.mrg-E7" TYPE="IDENT">they</COREF> came very close to the performance of regular mice that *T*-2 have not been genetically engineered *-3 *PRO*-4 to resemble <COREF ID="2" TYPE="IDENT">Alzheimer 's Disease</COREF> .
A second <COREF ID="2" TYPE="IDENT">Alzheimer 's</COREF> vaccine experiment was also reported *-1 in <COREF ID="16" TYPE="IDENT"><COREF ID="108" TYPE="APPOS" SUBTYPE="ATTRIB">the journal</COREF> <COREF ID="108" TYPE="APPOS" SUBTYPE="HEAD">Nature</COREF></COREF> by a group of University of South Florida scientists in Tampa .
In a third published paper <COREF ID="114" TYPE="IDENT">researchers</COREF> formally described how <COREF ID="114" TYPE="IDENT">they</COREF> genetically engineered a mouse model of <COREF ID="2" TYPE="IDENT">Alzheimer 's</COREF> similar to the human disease , complete with memory and learning impairment *T*-1 .
Neuroscientist Paul Chapman of the Cardiff School of Bio-Sciences in Wales , wrote an article in <COREF ID="16" TYPE="IDENT">the magazine</COREF> *PRO*-1 commenting on the developments .
<COREF ID="130" TYPE="IDENT">We all</COREF> know 0 <COREF ID="130" TYPE="IDENT">we</COREF> 've got a long way 0 *PRO* to go *T*-1 before <COREF ID="130" TYPE="IDENT">we</COREF> have a cure for <COREF ID="2" TYPE="IDENT">Alzheimer 's Disease</COREF> , but in order *PRO* to get there <COREF ID="130" TYPE="IDENT">we</COREF> need *-4 to have confidence that <COREF ID="130" TYPE="IDENT">we</COREF> understand <COREF ID="2" TYPE="IDENT">the disease</COREF> and that <COREF ID="130" TYPE="IDENT">we</COREF> have what <COREF ID="130" TYPE="IDENT">we</COREF> call *T*-5 *PRO*-2 a model system for *PRO* predicting whether <COREF ID="153" TYPE="IDENT">these treatments</COREF> will work .
And the fact that these papers are now showing <COREF ID="130" TYPE="IDENT">us</COREF> that behaviorally <COREF ID="151" TYPE="IDENT">these models</COREF> do what humans do *T*-1 , that is <COREF ID="151" TYPE="IDENT">they</COREF> behave more poorly as <COREF ID="151" TYPE="IDENT">they</COREF> age if <COREF ID="151" TYPE="IDENT">they</COREF> have <COREF ID="2" TYPE="IDENT">Alzheimer 's</COREF> genes , and that <COREF ID="153" TYPE="IDENT">these treatments</COREF> can reverse that , it just means 0 <COREF ID="130" TYPE="IDENT">we</COREF> have that much more confidence 0 <COREF ID="153" TYPE="IDENT">these treatments</COREF> will work in humans .
In a related development an international team of researchers reports in the latest issue of <COREF ID="177" TYPE="APPOS" SUBTYPE="ATTRIB">the journal</COREF> <COREF ID="177" TYPE="APPOS" SUBTYPE="HEAD">Science</COREF> , that a genetic mutation in an area of chromosome ten may put some people at increased risk of <COREF ID="186" TYPE="APPOS" SUBTYPE="HEAD">late onset Alzheimer 's Disease</COREF> , <COREF ID="186" TYPE="APPOS" SUBTYPE="ATTRIB">the most common form of dementia in the elderly</COREF> .
<COREF ID="9" TYPE="IDENT">Jessica Berman</COREF> , VOA News , Washington .
</TEXT>
</DOC>
